Vertex Pharmaceuticals Inc

Chart & Performance

D1W1MN

P/E

28.83

P/S

10.58

EPS

14.06

Div Yield, %

0.00%

Shrs. gr., 5y

0.10%

Rev. gr., 5y

26.49%

Revenues

9.87b

+10.51%

Net income

3.62b

+8.96%

CFO

3.54b

-14.35%

Earnings

Feb 03, 2025

Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of age or older who have at least one F508del mutation. Its pipeline includes VX-864 for the treatment of AAT deficiency, which is in Phase 2 clinical trial; VX-147 for the treatment of APOL1-mediated focal segmental glomerulosclerosis, or FSGS, and other serious kidney diseases which is in Phase 2 clinical trial; VX- 880, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-548, a NaV1.8 inhibitor for treatments of acute, neuropathic, musculoskeletal pain which is in Phase 2 clinical trial; and CTX001 for the treatment severe SCD and TDT which is in Phase 3 clinical trial. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. It has collaborations with Affinia Therapeutics, Inc.; Arbor Biotechnologies, Inc.; CRISPR Therapeutics AG.; Kymera Therapeutics, Inc.; Mammoth Biosciences, Inc.; Moderna, Inc.; Obsidian Therapeutics, Inc.; and Skyhawk Therapeutics, Inc.; as well as Ribometrix, Inc.; Genomics plc; Merck KGaA; Darmstadt, Germany, and X-Chem, Inc. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.

URL

https://www.vrtx.com/

IPO date

Jul 24, 1991

Employees

4,800

Domiciled in

Incorporated in

Valuation

Order:

Title USD in thousands, except ratios and share amounts	FY	FY	FY	FY	FY	FY	FY	FY	FY	FY
Title USD in thousands, except ratios and share amounts	2023‑12	2022‑12	2021‑12	2020‑12	2019‑12	2018‑12	2017‑12	2016‑12	2015‑12	2014‑12
Income
Revenues	9,869,200 10.51%	8,930,700 17.91%	7,574,400 22.06%
Cost of revenue	4,425,100	3,620,600	3,955,300
Unusual Expense (Income)
NOPBT	5,444,100	5,310,100	3,619,100
NOPBT Margin	55.16%	59.46%	47.78%
Operating Taxes	760,200	910,400	388,300
Tax Rate	13.96%	17.14%	10.73%
NOPAT	4,683,900	4,399,700	3,230,800
Net income	3,619,600 8.96%	3,322,000 41.84%	2,342,100 -13.63%
Dividends
Dividend yield
Proceeds from repurchase of equity	(293,000)	14,300	(1,459,300)
BB yield	0.28%	-0.02%	2.56%
Debt
Debt current	83,700	89,400	46,900
Long-term debt	2,174,100	943,200	1,113,400
Deferred revenue
Other long-term liabilities	153,000	1,336,000	902,200
Net debt	(11,556,900)	(9,845,300)	(6,450,400)
Cash flow
Cash from operating activities	3,537,300	4,129,900	2,643,500
CAPEX	(200,400)	(204,700)	(235,000)
Cash from investing activities	(3,141,700)	(321,100)	(340,900)
Cash from financing activities	(562,200)	(67,700)	(1,478,000)
FCF	4,339,400	4,385,400	3,095,234
Balance
Cash	11,218,300	10,778,500	7,524,900
Long term investments	2,596,400	99,400	85,800
Excess cash	13,321,240	10,431,365	7,231,980
Stockholders' equity	10,130,700	6,526,200	3,219,200
Invested Capital	9,135,800	9,160,200	8,175,300
ROIC	51.20%	50.76%	36.90%
ROCE	28.26%	33.85%	31.76%
EV
Common stock shares outstanding	260,500	259,100	259,900
Price	406.89 40.90%	288.78 31.50%	219.60 -7.08%
Market cap	105,994,845 41.66%	74,822,898 31.10%	57,074,040 -8.32%
EV	94,437,945	64,977,598	50,623,640
EBITDA	5,625,400	5,458,400	3,744,700
EV/EBITDA	16.79	11.90	13.52
Interest	44,100	54,800	61,500
Interest/NOPBT	0.81%	1.03%	1.70%